Sareum Holdings (SAR)

 

SAR Share PerformanceMore

52 week high1.6400 27/09/16
52 week low0.1733 04/01/16
52 week change 1.1600 (483.33%)
4 week volume180,192,072 01/09/16

Latest NewsMore

Licence agreement for Chk1 Inhibitor CCT245737

RNS Number: 9649K Sareum Holdings PLC 27 September 2016 (AIM: SAR) 27 September 2016 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Licence agreement for Chk1 Inhibitor CCT245737 Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, is pleased to announce that its co-investment partner, the CRT Pi...

Sareum confirms patent grants for Aurora+FLT3

Sareum Holdings said China's Patent Office and the Hong Kong Patents Registry have issued notifications that patents will...

China & HK Patent Grants for Sareum's Aurora+FLT3

RNS Number: 0463G Sareum Holdings PLC 03 August 2016 (AIM: SAR) 3 August 2016 SAREUM HOLDINGS PLC ("Sareum" or "the Company") China and Hong Kong Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors Sareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that the Chinese Patent Office ...

Sareum comments on share-price move

Sareum Holdings has noted the movement in its share price on Wednesday and pointed to an article published by Institute...

Movement in share price

RNS Number: 4505F Sareum Holdings PLC 28 July 2016 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Movement in share price Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, notes the movement in its share price on 27 July 2016. An article was published by the Institute of Cancer Research ("ICR") in M...

Clinical Trials CHK1 Inhibitor CCT245737 to Open

RNS Number: 0045Z Sareum Holdings PLC 23 May 2016 (AIM: SAR) 23 May 2016 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Clinical Trials of CHK1 Inhibitor CCT245737 to Open at the Royal Marsden Hospital Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, is pleased to announce that the Phase I clin...

Sareum appoints Stephen Parker as chairman

Sareum Holdings has appointed Stephen Parker as non-executive chairman, succeeding Paul Harper with immediate effect...

Change of Director

RNS Number: 3847Y Sareum Holdings PLC 17 May 2016 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Change of Director Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, is pleased to announce the appointment of Dr Stephen Parker as Non-executive Chairman of the Company. Dr Stephen Parker succe...

Fundamental DataMore

EPS-0.06
Dividend yield0 %

Equity Research (SAR)

Sareum Holdings plc
08/08/2016
The specialist cancer drug discovery and development business has announced that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted...
Sareum Holdings plc
08/04/2016
Sareum announced this week that its application for two Phase 1 clinical trials under its CHK 1 inhibitor programme, had received regulatory approval and that dosing is expected to begin during the...
Sareum Holdings plc
01/03/2016
The specialist cancer drug discovery and development business last week announced a Research and Co-Development Collaboration update as well as its interim results. Investor attention is currently...

Latest discussion posts More

  • Where's the target now then.

    Happy is not the word really... This could easily be a 10-20 multiple share very quickly. Wow!!
    27-Sep-2016
    barno99
  • Re: news Tuesday, watch this space

    Only a month out!! Well done, anyway. CN - Finally at break-even
    27-Sep-2016
    Chard Nick
  • 5p+ Target!

    As a minimum to me, added to SOU and SOLG. Happy days.
    27-Sep-2016
    alltold9

Users' HoldingsMore

Users who hold Sareum Holdings also hold..
RANGE RES.18%
LLOYDS GRP.17%
ROCKHOPPER15%
SOLO OIL14%
ID:ISIN:BMG4209G124414%

Codes & Symbols

ISINGB00B02RFS12
SymbolsSAR, LSE:SAR, SAR.L, SAR:LN, LON:SAR, XLON:SAR